A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lorukafusp alfa (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 09 Mar 2020 Results of outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2 has been published in the Clinical Cancer Research
- 03 Oct 2019 Status changed from active, no longer recruiting to completed.
- 03 Jun 2015 Planned End Date changed from 1 Dec 2011 to 1 Jan 2020 as per ClinicalTrials.gov record.